Table 1

Baseline table with patient, tumor, irAE, and response characteristics

CharacteristicsN total=143
Sex, per cent male (n)61.5 (88)
Age, median (range)64 (21–90)
BMI, median (range)27 (19–42)
Smoking, per cent (n)
 Never49.7 (71)
 Former32.9 (47)
 Current13.3 (19)
 Unknown4.2 (6)
History of auto-immune disease, per cent (n)4.9 (7)*
Use of immune suppressants prior to start anti-PD-1, per cent (n)7.0 (10)†
Melanoma subtype, per cent (n)
 Cutaneous85.3 (122)
 Acral4.2 (6)
 Mucosal1.4 (2)
 Unknown primary9.1 (13)
Performance score, per cent (n)
 071.3 (102)
 123.8 (34)
 20.7 (1)
 Unknown4.2 (6)
LDH level, per cent (n)
 Normal88.1 (126)
 1–2×ULN11.2 (16)
 ≥2×ULN0.7 (1)
Stage at time of anti-PD-1 initiation, per cent (n)
 III49.7 (71)
  IIIa4.9 (7)
  IIIb15.4 (22)
  IIIc22.4 (32)
  IIIc (irresectable)2.8 (4)
 IV50.3 (72)
  M1a7.7 (11)
  M1b11.2 (16)
  M1c14.7 (21)
  M1d11.2 (16)
  IV (resected)5.5 (8)
Treatment, per cent (n)
 Nivolumab54.5 (78)
 Pembrolizumab35 (50)
 Ipilimumab-nivolumab10.5 (15)
Intention, per cent (n)
 Adjuvant51.7 (74)
 Palliative48.3 (69)
Date OnTx blood draw in weeks after anti-PD-1 initiation, mean (range)12.8 (7.9–20.1)
Number of patients with irAEs, per cent (n)50.1 (86)
Total toxicities, per cent of total irAEs (n)169
 Grades 1–281.1 (137)
 Grades 3–418.9 (32)
Type of toxicity, n
 Arthralgia/arthritis5
 Colitis9
 Dermatitis24
 Hepatitis7
 Hypophysitis8
 Thyroiditis25
 Uveitis1
 Sicca19
Use of immune suppressants because of toxicity, per cent (n)21.0 (30)
Response, per cent (n)
 Adj – no relapse68.9 (51)
 Adj – relapse31.1 (23)
 Pall – clinical benefit‡69.6 (48)
 Pall – progression§30.4 (21)
  • *Ulcerative colitis (2), rheumatoid arthritis (1), psoriasis (1), diabetes mellitus type I (1), celiac disease (1), pre-existing hypothyroidism (1).

  • †Dexamethasone (brain radiotherapy, 8), mesalazine (ulcerative colitis, 1), methotrexate (rheumatoid arthritis, discontinued shortly prior to first cycle, 1).

  • ‡Defined as complete response, partial response, stable disease.

  • §Defined as progressive disease.

  • Adj, adjuvant treatment; BMI, body mass index; irAEs, immune-related adverse events ; LDH, lactate dehydrogenase; N, number; OnTx, on treatment; Pall, palliative treatment; PD-1, programmed cell death protein-1 ; UNL, upper limit of normal.